BACKGROUND	A double-blind , randomized , parallel-group , placebo-controlled trial was conducted in patients with paroxysmal atrial fibrillation or flutter ( PAF/PAFL ) experiencing 2 or more episodes of symptomatic PAF/PAFL during a 28-day observation period to determine the dose-response effect and safety of flecainide .\